Ibrutinib-Navitoclax was ranked as the third-best combination for further study; such combinations (Ibrutinib with Bcl2 inhibitors) have shown promising results in phase II clinic trial (NCT02756897) for chronic lymphocytic leukemia (CLL), and recently suggested as the first-line treatment for CLL [10]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.